BioCryst Pharmaceuticals | BCRX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Chugai Pharma JPY 1.65B 0 2026-09
Daiichi Sankyo JPY 1.82B 1.68M 2026-09
DBV Technologies USD 235.6M 98.78M 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
Glaxosmithkline GBP 2.02B 2.03B 2026-09
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novavax USD 162.58M 106K 2025-12
PTC Therapeutics USD 83.33M 445K 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sarepta Therapeutics USD 107.23M 1.61M 2026-09
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Vertex Pharmaceuticals USD 253.5M 200K 2026-09